Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
14 Liraglutide and semaglutide, originally developed for people with Type 2 diabetes mellitus (T2DM), are approved for chronic weight management in people with obesity (or overweight and 1 weight-related comorbidities
This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 50 print issues and online access 269,00 per year only 5,38 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
Schedule your consultation today, and explore the best weight loss solutions near you
& McCarthy, M
While the drug is approved for type 2 diabetes management and cardiovascular risk reduction in high-risk patients with diabetes, it contains the same active ingredient (semaglutide) as Wegovy, but costs less than the injection
US$ 26.57
US$ 24.86
US$ 21.91
US$ 26.72
US$ 24.16
US$ 29.03
US$ 28.64
